This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10: D03 | D03.0 melanoma in situ of lip | D03.1 melanoma in situ of eyelid, including canthus | D03.2 melanoma in situ of ear and external auricular canal | D03.3 melanoma in situ of face | D03.4 melanoma in situ of scalp and neck | D03.5 melanoma in situ of trunk | D03.6 melanoma in situ of upper limb, including shoulder | D03.7 melanoma in situ of lower limb, including hip | D03.8 other sites | Special Copayment Reduction V193 (copayment 5%, for 5 years from registration) |
| B. Synonyms | Melanoma in situ (MIS), lentigo maligna (Hutchinson melanotic freckle), superficial spreading melanoma in situ, acral lentiginous MIS, Clark level I melanoma, radial growth phase melanoma |
| C. Adult onset | Very high — the lentigo maligna type is common on senile photodamaged skin in the 50s–80s; the superficial spreading type in the 20s–50s; the acral type, on the palms, soles and under the nails, is relatively common in Koreans |
| Contents | 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References |
| 1. History summary | Hutchinson (1890) first described lentigo maligna; Clark (1969) established the depth-of-invasion grading system; clinical introduction of the dermoscope in the 1990s revolutionized early diagnosis. |
| 2. Causes summary | Cumulative ultraviolet (UV) exposure and intermittent sunburn; fair skin (Fitzpatrick types I-II); family history; multiple atypical nevi; immunosuppression. |
| 3. Genetics summary | BRAF V600E (superficial spreading type); KIT mutation (acral and mucosal types); CDKN2A germline mutation (familial); MC1R (UV sensitivity). |
| 4. Epidemiology summary | Incidence increasing worldwide; most common in White populations, but Koreans have a high proportion of the acral type (about 40-60%). |
| 5. Pathophysiology summary | UV → melanocyte DNA damage (C→T transitions) → radial growth of atypical melanocytes → stage confined to the epidermis (MIS). |
| 6. Symptoms summary | ABCDE changes in pigmented lesions (asymmetry, irregular border, color variation, diameter >6mm, evolution); mostly asymptomatic. |
| 7. Signs summary | Atypical pigment network, regression structures and blue-white veil on dermoscopy; reflectance confocal microscopy; total body photography. |
| 8. Screening summary | Total body skin examination + dermoscopy; surveillance every 6-12 months for high-risk groups (immunosuppressed, prior melanoma, family history). |
| 9. Diagnosis summary | Complete excisional biopsy (5mm margin); dermoscopy; reflectance confocal microscopy; histopathologic confirmation of Clark level I. |
| 10. Treatment summary | Wide local excision (5-10mm margin); sentinel lymph node biopsy unnecessary if there is no invasive component; dermoscopic surveillance for recurrent lesions. |
| 11. Prognosis summary | 5-year survival nearly 100%; low recurrence rate after complete excision; prognosis worsens sharply on progression to invasive melanoma. |
| 12. Prevention summary | SPF 50+ sunscreen; protective clothing; no tanning; regular skin self-examination and specialist examination. |
The history of melanoma in situ (MIS) developed within the history of melanoma as a whole. The description of black tumors by the British surgeon Robert Carswell in 1838 marks the beginning of the modern concept of melanoma, and in 1890 Sir Jonathan Hutchinson first described in detail a slowly growing brown macular lesion arising on the faces of elderly people and named it "Hutchinson melanotic freckle." This is the oldest record of the melanoma in situ known today as lentigo maligna.
1969 was an important turning point in the history of melanoma pathology. In a paper published with colleagues in the American Journal of Pathology, Wallace H. Clark Jr. established the Clark levels system (I-V) based on the depth of dermal invasion of melanoma. Clark level I defines atypical melanocytes confined to the epidermis, i.e., melanoma in situ, and this concept became the basis for clearly distinguishing melanoma in situ from invasive melanoma. In 1970, Alexander Breslow went beyond Clark levels and proposed the concept of Breslow thickness, directly measuring tumor thickness (mm), improving the accuracy of melanoma prognosis.
The distinction between lentigo maligna and lentigo maligna melanoma was established in the 1970s–80s, and the lentigo maligna stage was confirmed to be melanoma in situ. The clinical introduction of dermoscopy began in earnest in the 1990s, and with Stolz's establishment of the ABCD criteria in 1994 and the subsequent development of various pattern recognition algorithms, the accuracy of clinical diagnosis of melanoma in situ improved greatly. The introduction of reflectance confocal microscopy (RCM), enabling noninvasive assessment at the histologic level, is the major advance of the past 20 years.
Ultraviolet (UV) exposure is the most important environmental risk factor for melanoma in situ. UV is divided by wavelength into UVA (315-400nm) and UVB (280-315nm), and UVB causes direct DNA damage (cytosine dimer formation, C→T transitions), promoting melanocyte mutations. The lentigo maligna type arises on senile photodamaged skin of the head and neck that has received decades of chronic cumulative UV exposure, while intermittent intense sunburn plays a more important role in the superficial spreading type.
Artificial UV exposure (indoor tanning devices, tanning beds) also significantly increases melanoma risk, and the WHO has classified it as a Group 1 carcinogen. Skin type: Fitzpatrick type I-II skin, which is fair and heavily freckled, is at highest risk. Red or blond hair and blue eyes are also related risk factors. Number of nevi (moles): melanoma risk increases with 5 or more atypical (dysplastic) nevi or 50 or more nevi in total. Family history: having a first-degree relative with melanoma increases the risk 2-3-fold, and carriers of CDKN2A germline mutations have a lifetime cumulative melanoma risk of up to 70%. Immunosuppression (organ transplantation, HIV): melanoma risk increases 2-8-fold due to impaired immune surveillance.
In East Asians, including Koreans, acral lentiginous melanoma arising on the feet and hands (especially the palms, soles and around the nails) accounts for 40-60% of all melanomas; this type is known to have a relatively weak direct link to UV exposure, with weight bearing and chronic repetitive trauma involved.
The main genetic changes differ by molecular subtype of melanoma in situ. BRAF V600E mutation is found in about 50-60% of superficial spreading melanomas and is present even at the in situ stage. BRAF V600E constitutively activates the MAPK signaling pathway, promoting melanocyte proliferation, but is not sufficient on its own, and additional genetic events are required.
KIT mutations occur at a relatively high rate (10-20%) in acral lentiginous and mucosal melanomas and are of great clinical importance in Korean melanoma. KIT mutations activate the SCF/KIT receptor tyrosine kinase pathway. NRAS mutations are found in about 15-20% of melanomas. CDKN2A (p16/ARF) germline mutations cause familial atypical multiple mole melanoma (FAMMM) syndrome and are associated with a lifetime cumulative melanoma risk of 70%. MC1R (melanocortin 1 receptor) variants are associated with red or blond hair, freckles and Fitzpatrick type I-II skin and increase melanoma risk by raising UV sensitivity. In the lentigo maligna type, UV-signature C→T transition mutations occur at very high frequency across the whole genome (a subtype with a high UV mutational burden), and TERT promoter mutations contribute to cell immortalization through telomerase reactivation.
The incidence of melanoma in situ continues to rise worldwide. In the United States, melanoma incidence has increased by about 3-4%/year in recent decades, and the proportion accounted for by melanoma in situ has also been increasing. Australia and New Zealand have the highest melanoma incidence in the world (30-40 per 100,000 population). Europe shows a latitude paradox pattern, with incidence decreasing from north to south.
In Korea, about 700-1,000 cases of melanoma (including invasive) occur annually, lower than the world average. However, the acral lentiginous type accounts for about 40-60% of melanomas in Koreans, a different clinical picture from that of Western (White) people, in whom it is about 5%. In Koreans, the lentigo maligna type is relatively common among elderly people in rural areas with heavy UV exposure. The proportion diagnosed at the melanoma in situ stage is about 20-30% of all melanomas and is higher in countries where specialist dermatologic screening is active.
Melanoma in situ develops through a multistep process starting in the melanocytes of the epidermal basal layer. Ultraviolet light (especially UVB) causes direct damage to melanocyte DNA (cyclobutane pyrimidine dimers, C→T and CC→TT transitions), and when this damage is not adequately repaired, mutations become permanent.
When BRAF V600E or NRAS Q61 mutations occur as early events, melanocytes begin to proliferate like a benign nevus. When TERT promoter mutations, CDKN2A loss, PTEN loss and others accumulate in addition, cell cycle inhibitory mechanisms are disabled and cell immortalization occurs, so that atypical melanocytes undergo radial growth along the epidermal basal layer. This stage is melanoma in situ, in which the basement membrane has not yet been invaded. Lentigo maligna shows a pattern of horizontal expansion of atypical melanocytes along the basal layer in chronically photodamaged skin, growing slowly over decades. When an invasive component develops, it transforms into lentigo maligna melanoma. In the acral type, KIT pathway activation and copy number alterations (CNA) are the main mechanisms, independent of UV.
Melanoma in situ mostly presents as a pigmented skin lesion meeting the ABCDE criteria. A (Asymmetry): the two halves of the lesion have different shapes. B (Border irregularity): the border of the lesion is jagged or ill-defined. C (Color variation): two or more shades such as brown, black, reddish-brown and blue-gray are mixed within the same lesion. D (Diameter): diameter of 6mm or more (larger than a pencil eraser). E (Evolution): changes in size, shape or color are observed over weeks to months.
Lentigo maligna is usually found over several years as a slowly growing, irregular brown-to-black macule on heavily sun-exposed areas such as the face, behind the ears and the neck, and in many patients diagnosis is delayed even though they have been aware of the pigmented lesion for a long time. Acral lentiginous melanoma in situ presents as irregular pigmented macules on the palms and soles or black streaks under the nails (melanonychia striata), and is easily mistaken by nonspecialists for a bruise or mole. It is mostly asymptomatic; if itching or pain is present, an invasive component should be suspected.
Dermoscopy findings are key to diagnosis. In superficial spreading MIS, atypical pigment network, blue-white veil, reverse white pigment network and atypical dots/globules are observed. In lentigo maligna, atypical pigmented dots on dermoscopy (involving the follicular openings pattern), oblique streaks and gray dots are characteristic.
Reflectance confocal microscopy (RCM): obtains real-time histologic-level images from the skin surface to a depth of 2-3mm. In lentigo maligna, it noninvasively confirms the basal-layer distribution of atypical melanocytes and pagetoid spread. RCM is particularly useful for assessing dermal invasion in lentigo maligna. Wood lamp examination: shows the extent of lentigo maligna lesions as wider than seen with the naked eye, helping set surgical margins. Histopathologic findings: Clark level I (confined to the epidermis), proliferation of atypical melanocytes in the epidermal basal layer with pagetoid spread, and an intact basement membrane. Confirmed with the MIB-1 (Ki-67) proliferation index and SOX10, Melan-A and HMB-45 immunostaining.
In Korea, there is no separate national cancer screening program for melanoma. However, active screening is recommended in the following high-risk groups. Total body skin examination (TBSE) for high-risk groups: total body skin examination including dermoscopy is performed every 6-12 months in those with a prior history of melanoma, a first-degree family history of melanoma, CDKN2A germline mutation carriers, many atypical nevi (50 or more), Fitzpatrick type I-II skin, and a history of severe sunburn in childhood.
Total body photography (TBP): a method in which baseline photographs are taken in high-risk groups with many atypical nevi and compared at follow-up to detect new lesions or changes. Digital dermoscopy follow-up: dermoscopic images of individual atypical nevi are compared at 3-6-month intervals to detect changes. Immunosuppressed patients (organ transplantation, HIV), patients with xeroderma pigmentosum, and skin in radiotherapy fields require more frequent examinations. Public awareness education campaigns (teaching the ABCDE self-examination method) also contribute to early detection.
Melanoma in situ must be confirmed by histopathologic examination. Complete excisional biopsy of the suspicious lesion is the most recommended method, with an elliptical excision including 2-5mm of surrounding normal skin providing diagnosis and initial treatment at the same time. For large lentigo maligna lesions, a punch biopsy or incisional biopsy may be taken from a representative area (such as the darkest part).
Histopathologic assessment: proliferation of atypical melanocytes confined to the epidermal basal layer, growth along the basal layer as single cells or small nests, pagetoid spread (single-cell spread into the upper epidermis), and an intact basement membrane are the key findings of MIS. Breslow thickness measurement is essential to differentiate invasive melanoma. Immunohistochemistry: melanocytic lineage is confirmed with S100, Melan-A (MART-1), HMB-45 and SOX10. Dermoscopy: used before biopsy to estimate malignancy and select a representative area. FISH (fluorescence in situ hybridization): when distinguishing a benign nevus from melanoma is difficult, analysis of RREB1 (6p25), MYB (6q23), CCND1 (11q13) and CEP6 is used as an adjunct to diagnosis.
The standard treatment for melanoma in situ is wide local excision (WLE). Margin recommendations: the US NCCN and European guidelines recommend 5-10mm margins for MIS. The lentigo maligna type often requires wider margins (10mm or more), and several studies have reported high rates of positive margins even with 5mm margins, so there is a tendency to recommend 10mm or more.
Mohs micrographic surgery or modified Mohs surgery: a method of excision while confirming negative margins for lentigo maligna melanoma in situ at sites where tissue preservation is important, such as the face, digits and perianal area; it significantly lowers the local recurrence rate. Sentinel lymph node biopsy (SLNB): SLNB is not performed in pure MIS without an invasive component (Breslow thickness >0.8mm or T1b or higher). When an invasive component is present, SLNB is considered according to standard indications. After excision, a dermoscopic surveillance plan for remaining atypical nevi is established, and regular total body skin examinations are performed for early detection of metachronous melanomas at other sites.
With complete excision, melanoma in situ has a very favorable prognosis, with a 5-year survival rate of nearly 100%. Because the basement membrane has not been invaded, there is no risk of metastasis, and the recurrence rate after excision with adequate margins is less than 5%. Factors that worsen prognosis are incomplete excision (positive margins) and delayed diagnosis.
The lentigo maligna type grows slowly over years and in some cases progresses to invasive melanoma (lentigo maligna melanoma, LMM). On progression to invasive disease, prognosis is determined by Breslow thickness, and even T1a (thickness ≤0.8mm, no ulceration) invasive melanoma has a high 5-year survival rate of more than 95%. However, once metastasis occurs, prognosis becomes very poor, so complete excision at the in situ stage is decisive. After treatment, total body skin examination is performed every 6-12 months for 5 years, and regular checkups continue for life thereafter. In familial melanoma (CDKN2A mutation carriers), the risk of metachronous melanoma is high, so more frequent surveillance is needed.
Sun protection is the most effective means of prevention. Apply a broad-spectrum sunscreen of SPF 50+ PA+++ or higher daily to all exposed areas and reapply every 2-3 hours. Limit outdoor activity between 10 a.m. and 4 p.m., when UV is strongest, and wear long-sleeved clothing and a UV-protective hat. Wearing UV-protective fabric (UPF 50+) is effective.
No use of artificial tanning devices: indoor tanning (tanning beds) is a WHO Group 1 carcinogen and increases melanoma risk by up to 75%, particularly when used before age 30. Skin self-examination education: patients are taught monthly skin self-examination using the ABCDE criteria and advised to see a dermatologist immediately for any changing lesion. Regular specialist examination: total body skin examination including dermoscopy is performed every 6-12 months in high-risk groups. In Korea, raising awareness of acral melanoma is particularly important, and attention should be paid to pigment changes on the palms, soles and nails. Genetic counseling: genetic counseling and participation in early screening programs are recommended for familial melanoma kindreds with confirmed CDKN2A germline mutations.